Premium
Comparison of injection‐site reactions between the etanercept biosimilar SB 4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study
Author(s) -
Girolomoni G.,
Feldman S.R.,
Emery P.,
Ghil J.,
Keum J.W.,
Cheong S.Y.,
Hong E.
Publication year - 2018
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.16032
Subject(s) - etanercept , discontinuation , medicine , rheumatoid arthritis , biosimilar , injection site , erythema , dermatology , itching , adverse effect , incidence (geometry) , pharmacology , surgery , physics , optics
Injection site reactions (ISRs) are common adverse reactions to biologic drugs, consisting of itching, erythema, and induration at the injection site1. ISRs usually appear within 24-48 hours after injection and subside within a few days. They typically occur in the first two months of treatment and subsequently decrease in frequency; incidence varies by drug. While ISRs seldom result in discontinuation of treatment, ISRs remain a safety concern when using biologic drugs. This article is protected by copyright. All rights reserved.